Insights into the structural determinants for selective inhibition of nitric oxide synthase isoforms

AbstractSelective inhibition of the nitric oxide synthase isoforms (NOS) is a promising approach for the treatment of various disorders. However, given the high active site conservation among all NOS isoforms, the design of selective inhibitors is a challenging task. Analysis of the X-ray crystal structures of the NOS isoforms complexed with known inhibitors most often gives no clues about the structural determinants behind the selective inhibition since the inhibitors share the same binding conformation. Aimed at a better understanding of the structural factors responsible for selective inhibition of NOS isoforms we have performed MD simulations for iNOS, nNOS and eNOS complexed with Nω-NO2-L-Arg (1), and with the aminopyridine derivatives 2 and 3. The slightly better selectivity of 1 for nNOS may be assigned to the presence of extra charge–charge interactions due to its “extended” conformation. While the high affinity of 2 for iNOS can be explained by the formation of an iNOS-specific subpocket upon binding, the lack of affinity for eNOS is associated to a conformational change in Glu363. The strong van der Waals and electrostatic interactions between 3 and the active site of nNOS are most likely responsible for its higher affinity for this isoform. Owing to the elongated and narrow binding pocket of iNOS, the correct positioning of 3 over the heme group is difficult, which may account for its lower affinity toward this isoform. Brought together, our results might help to rationalize the design of selective NOS inhibitors. FigureOverall RMSD of the protein backbone over 8 ns simulation is shown for the complexes 3:eNOSmonomer and 3:eNOSdimer

[1]  G. Desiraju,et al.  Insights into ligand selectivity in nitric oxide synthase isoforms: a molecular dynamics study. , 2007, Journal of molecular graphics & modelling.

[2]  Richard Graham Knowles,et al.  1400W Is a Slow, Tight Binding, and Highly Selective Inhibitor of Inducible Nitric-oxide Synthase in Vitro and in Vivo* , 1997, The Journal of Biological Chemistry.

[3]  M. Botta,et al.  Computational studies of competitive inhibitors of nitric oxide synthase (NOS) enzymes: towards the development of powerful and isoform-selective inhibitors. , 2006, Current medicinal chemistry.

[4]  J. Leiper,et al.  The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis , 2011, Nature Reviews Drug Discovery.

[5]  Piotr Cieplak,et al.  R.E.D. Server: a web service for deriving RESP and ESP charges and building force field libraries for new molecules and molecular fragments , 2011, Nucleic Acids Res..

[6]  António E. N. Ferreira,et al.  Re and Tc tricarbonyl complexes: from the suppression of NO biosynthesis in macrophages to in vivo targeting of inducible nitric oxide synthase. , 2010, Bioconjugate chemistry.

[7]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[8]  T. Poulos,et al.  Crystal Structures of Zinc-free and -bound Heme Domain of Human Inducible Nitric-oxide Synthase , 1999, The Journal of Biological Chemistry.

[9]  S. Nosé A molecular dynamics method for simulations in the canonical ensemble , 1984 .

[10]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[11]  C. Thiemermann,et al.  Nitric oxide synthase inhibitors. , 2000, Methods in molecular medicine.

[12]  T. Poulos,et al.  Mapping the active site polarity in structures of endothelial nitric oxide synthase heme domain complexed with isothioureas. , 2000, Journal of inorganic biochemistry.

[13]  P. Weber,et al.  Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation , 1999, Nature Structural Biology.

[14]  Piotr Cieplak,et al.  R.E.DD.B.: A database for RESP and ESP atomic charges, and force field libraries , 2007, Nucleic Acids Res..

[15]  T. Poulos,et al.  Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors. , 2008, Journal of the American Chemical Society.

[16]  António E. N. Ferreira,et al.  Targeting nitric oxide synthase with 99mTc/Re-tricarbonyl complexes containing pendant guanidino or isothiourea moieties , 2011 .

[17]  T. Poulos,et al.  Unexpected binding modes of nitric oxide synthase inhibitors effective in the prevention of a cerebral palsy phenotype in an animal model. , 2010, Journal of the American Chemical Society.

[18]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[19]  James B. Mitchell,et al.  Nitric oxide and cancer: an introduction. , 2003, Free radical biology & medicine.

[20]  James Leiper,et al.  Blocking NO synthesis: how, where and why? , 2002, Nature Reviews Drug Discovery.

[21]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[22]  W. Delano The PyMOL Molecular Graphics System , 2002 .

[23]  K. Sharp,et al.  Travel depth, a new shape descriptor for macromolecules: application to ligand binding. , 2006, Journal of molecular biology.

[24]  T. Poulos,et al.  Exploration of the active site of neuronal nitric oxide synthase by the design and synthesis of pyrrolidinomethyl 2-aminopyridine derivatives. , 2010, Journal of medicinal chemistry.

[25]  J. Zicha,et al.  Hypertensive response to chronic NG-nitro-L-arginine methyl ester (L-NAME) treatment is similar in immature and adult Wistar rats. , 2003, Clinical science.

[26]  P. Kollman,et al.  A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .

[27]  T. Poulos,et al.  Crystallographic studies on endothelial nitric oxide synthase complexed with nitric oxide and mechanism-based inhibitors. , 2001, Biochemistry.

[28]  Roman Fedorov,et al.  Structural analysis of isoform-specific inhibitors targeting the tetrahydrobiopterin binding site of human nitric oxide synthases. , 2005, Journal of medicinal chemistry.

[29]  Hoover,et al.  Canonical dynamics: Equilibrium phase-space distributions. , 1985, Physical review. A, General physics.

[30]  V. Granik,et al.  Nitric oxide synthase inhibitors: biology and chemistry , 2002 .

[31]  J. Macdonald CHAPTER 23. NITRIC OXIDE SYNTHASE INHIBITORS , 1996 .

[32]  Gerhard Klebe,et al.  PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations , 2007, Nucleic Acids Res..

[33]  Haitao Ji,et al.  Selective neuronal nitric oxide synthase inhibitors. , 2005, Current topics in medicinal chemistry.

[34]  Jeremy R. Greenwood,et al.  Epik: a software program for pKa prediction and protonation state generation for drug-like molecules , 2007, J. Comput. Aided Mol. Des..

[35]  Piotr Cieplak,et al.  The R.E.D. tools: advances in RESP and ESP charge derivation and force field library building. , 2010, Physical chemistry chemical physics : PCCP.

[36]  P. Kollman,et al.  Application of RESP charges to calculate conformational energies, hydrogen bond energies, and free energies of solvation , 1993 .

[37]  Jan H. Jensen,et al.  Very fast empirical prediction and rationalization of protein pKa values , 2005, Proteins.

[38]  Kremer,et al.  Molecular dynamics simulation for polymers in the presence of a heat bath. , 1986, Physical review. A, General physics.

[39]  T. Poulos,et al.  Structure-function studies on nitric oxide synthases. , 2005, Journal of inorganic biochemistry.

[40]  Edsger W. Dijkstra,et al.  A note on two problems in connexion with graphs , 1959, Numerische Mathematik.

[41]  Alexander D. MacKerell,et al.  CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..

[42]  V. Cardile,et al.  Novel Inhibitors of Neuronal Nitric Oxide Synthase , 2003, Experimental biology and medicine.

[43]  T. Poulos,et al.  Potent, highly selective, and orally bioavailable gem-difluorinated monocationic inhibitors of neuronal nitric oxide synthase. , 2010, Journal of the American Chemical Society.

[44]  M. Moskowitz,et al.  Hypertension in mice lacking the gene for endothelial nitric oxide synthase , 1995, Nature.

[45]  Nathan A. Baker,et al.  PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations , 2004, Nucleic Acids Res..

[46]  Garrett M Morris,et al.  Conformational changes in nitric oxide synthases induced by chlorzoxazone and nitroindazoles: crystallographic and computational analyses of inhibitor potency. , 2002, Biochemistry.

[47]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[48]  C. Cooper,et al.  Nitric oxide synthases: structure, function and inhibition. , 2001, The Biochemical journal.

[49]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[50]  B. Brooks,et al.  Constant pressure molecular dynamics simulation: The Langevin piston method , 1995 .

[51]  J. Tainer,et al.  Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase , 2008, Nature chemical biology.

[52]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[53]  S. Shaik,et al.  Compound I of nitric oxide synthase: the active site protonation state. , 2007, Journal of the American Chemical Society.

[54]  I. Schlichting,et al.  Structural Basis for the Specificity of the Nitric-oxide Synthase Inhibitors W1400 and Nω-Propyl-l-Arg for the Inducible and Neuronal Isoforms* , 2003, Journal of Biological Chemistry.